General ~ Risk-Reducing Salpingo-Oophorectomy
~ Genetics of Breast & Ovarian Cancer

List was last updated on Nov 26, 2019 @ 7:39 am.


    • Preventing Ovarian Cancer in High-risk Women: One Surgery at a Time.
    • Swanson CL, Bakkum-Gamez JN.
    • Clin Obstet Gynecol. 2019 Nov 22. doi: 10.1097/GRF.0000000000000499. [Epub ahead of print]
    • Review
    • Prospective follow-up of quality of life for participants undergoing risk-reducing salpingo-oophorectomy or ovarian cancer screening in GOG-0199: An NRG Oncology/GOG study.
    • Mai PL, Huang HQ, Wenzel LB, Han PK, Moser RP, Rodriguez GC, Boggess J, Rutherford TJ, Cohn DE, Kauff ND, Phillips KA, Wilkinson K, Wenham RM, Hamilton C, Powell MA, Walker JL, Greene MH, Hensley ML.
    • Gynecol Oncol. 2019 Nov 21. pii: S0090-8258(19)31613-0. doi: 10.1016/j.ygyno.2019.10.026. [Epub ahead of print]
    • Use of antidepressants in women after prophylactic bilateral oophorectomy: A Danish national cohort study.
    • Abildgaard J, Ahlström MG, Nielsen DL, Daugaard G, Lindegaard B, Obel N, Lidegaard Ø.
    • Psychooncology. 2019 Nov 16. doi: 10.1002/pon.5290. [Epub ahead of print]
    • Menopausal hormone therapy for BRCA-mutation carriers: attitudes of Israeli healthcare providers before and after a brief educational intervention.
    • Perri T, Farhadian Y, Friedman E, Korach J.
    • Menopause. 2019 Nov 4. doi: 10.1097/GME.0000000000001432. [Epub ahead of print]
    • Sexual function, menopausal symptoms, depression and cancer worry in women with BRCA mutations.
    • Powell CB, Alabaster A, Le A, Stoller N, Armstrong MA, Raine-Bennett T.
    • Psychooncology. 2019 Oct 26. doi: 10.1002/pon.5253. [Epub ahead of print]
    • Does preventive oophorectomy increase the risk of depression in BRCA mutation carriers?
    • Kotsopoulos J, Gronwald J, Lubinski J, McCuaig J, Lynch HT, Neuhausen SL, Foulkes WD, Weitzel JN, Senter L, Tung N, Eng C, Karlan B, Sun P, Narod SA; Hereditary Breast Cancer Clinical Study Group.
    • Menopause. 2019 Oct 21. doi: 10.1097/GME.0000000000001437. [Epub ahead of print]
    • Exploring factors that impact uptake of risk-reducing bilateral salpingo-oophorectomy (RRBSO) in high-risk women.
    • Hickey M, Rio I, Trainer A, Marino JL, Wrede CD, Peate M.
    • Menopause. 2019 Oct 14. doi: 10.1097/GME.0000000000001422. [Epub ahead of print]
    • Interventions to improve psychosocial well-being in female BRCA-mutation carriers following risk-reducing surgery.
    • Jeffers L, Reid J, Fitzsimons D, Morrison PJ, Dempster M.
    • Cochrane Database Syst Rev. 2019 Oct 9;10:CD012894. doi: 10.1002/14651858.CD012894.pub2. [Epub ahead of print]
    • Review

    Original research:

    Mindfulness-based stress reduction for menopausal symptoms after risk-reducing salpingo-oophorectomy (PURSUE study): a randomised controlled trial.

    Original research:

    Addressing sexual dysfunction after risk-reducing salpingo-oophorectomy: effects of a brief, psychosexual intervention.

    • Risk-Reducing Salpingo-Oophorectomy and Breast Cancer Risk Reduction in the Gynecologic Oncology Group Protocol-0199 (GOG-0199).
    • Mai PL, Miller A, Gail MH, Skates S, Lu K, Sherman ME, Ioffe OB, Rodriguez G, Cohn DE, Boggess J, Rutherford T, Kauff ND, Rader JS, Phillips KA, DiSilvestro PA, Olawaiye AB, Ridgway MR, Greene MH, Piedmonte M, Walker JL.
    • JNCI Cancer Spectr. 2019 Oct 8; pkz075. doi: 10.1093/jncics/pkz075. eCollection 2019 Oct.

    Commentary:

    Preventing breast cancer in high risk women: is there still a role for oophorectomy?

    • A Cost-effectiveness Analysis of Multigene Testing for All Patients With Breast Cancer.
    • Sun L, Brentnall A, Patel S, Buist DSM, Bowles EJA, Evans DGR, Eccles D, Hopper J, Li S, Southey M, Duffy S, Cuzick J, Dos Santos Silva I, Miners A, Sadique Z, Yang L, Legood R, Manchanda R.
    • JAMA Oncol. 2019 Oct 3. doi: 10.1001/jamaoncol.2019.3323. [Epub ahead of print]

    CME Audio Interview: Cost-effectiveness of Multigene Testing for All Patients With Breast Cancer. (JN Learning : JAMA Oncology)

    Press: Study Finds Breast, Ovarian Cancer Gene Tests Cost-Effective for Unselected Breast Cancer Patients. (GenomeWeb)

    • Broad Application of Multigene Panel Testing for Breast Cancer Susceptibility-Pandora's Box Is Opening Wider.
    • Robson M, Domchek S.
    • JAMA Oncol. 2019 Oct 3. doi: 10.1001/jamaoncol.2019.4004. [Epub ahead of print]
    • Commentary
    • What information do healthcare professionals need to inform premenopausal women about risk-reducing salpingo-oophorectomy?
    • Hickey M, Rio I, Trainer A, Marino JL, Wrede CD, Peate M.
    • Menopause. 2019 Sep 16. doi: 10.1097/GME.0000000000001421. [Epub ahead of print]
    • Cost effectiveness of bilateral risk-reducing mastectomy and salpingo-oophorectomy.
    • Schrauder MG, Brunel-Geuder L, Häberle L, Wunderle M, Hoyer J, Csorba R, Reis A, Schulz-Wendtland R, Beckmann MW, Lux MP.
    • Eur J Med Res. 2019 Sep 14;24(1):32. doi: 10.1186/s40001-019-0391-8.
    • A comparison of ovarian cancer mortality in women with BRCA1 mutations undergoing annual ultrasound screening or preventive oophorectomy.
    • Gronwald J, Lubinski J, Huzarski T, Cybulski C, Menkiszak J, Siołek M, Stawicka M, Sun P, Kim S, Kotsopoulos J, Narod SA.
    • Gynecol Oncol. 2019 Sep 6. pii: S0090-8258(19)31486-6. doi: 10.1016/j.ygyno.2019.08.034. [Epub ahead of print]
    • Pathological findings following risk-reducing salpingo-oophorectomy in BRCA mutation carriers: A systematic review and meta-analysis.
    • Cheng A, Li L, Wu M, Lang J.
    • Eur J Surg Oncol. 2019 Sep 5. pii: S0748-7983(19)30662-6. doi: 10.1016/j.ejso.2019.09.002. [Epub ahead of print]
    • Health Care Provider Adherence to Surgical Guidelines for Risk-Reducing Salpingo-Oophorectomy.
    • Wilhite AM, Oestreich MC, Olson M, Bedell SM, Westenberg D, Bangdiwala A, Ikramuddin S, Sanchez-Avila M, Madoff RD, Khalifa MA, Erickson BK.
    • Obstet Gynecol. 2019 Sep;134(3):520-526. doi: 10.1097/AOG.0000000000003421.
    • Hysterectomy and Adenextomy via transvaginal natural orifice transluminal endoscopic surgery (vNOTES): A UK perspective with a case series of 33 patients.
    • Karkia R, Giacchino T, Taylor J, Ghaffar A, Gupta A, Kovoor E.
    • Eur J Obstet Gynecol Reprod Biol. 2019 Aug 31;242:29-32. doi: 10.1016/j.ejogrb.2019.08.023. [Epub ahead of print]
    • Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer: US Preventive Services Task Force Recommendation Statement.
    • US Preventive Services Task Force, Owens DK, Davidson KW, Krist AH, Barry MJ, Cabana M, Caughey AB, Doubeni CA, Epling JW Jr, Kubik M, Landefeld CS, Mangione CM, Pbert L, Silverstein M, Simon MA, Tseng CW, Wong JB.
    • JAMA. 2019 Aug 20;322(7):652-665. doi: 10.1001/jama.2019.10987.

    Evidence report, Review:

    Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer in Women: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.

    Guidelines [Internet]:

    Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA1/2-Related Cancer in Women: A Systematic Review for the U.S. Preventive Services Task Force [Internet].

    Editorial:

    Broadening Criteria for BRCA1/2 Evaluation: Placing the USPSTF Recommendation in Context.

    Editorial:

    USPSTF Recommendations for BRCA1 and BRCA2 Testing in the Context of a Transformative National Cancer Control Plan.

    Editorial:

    Hereditary Cancer Evaluation in 2019-a Rapidly Evolving Landscape.

    Editorial:

    US Preventive Services Task Force Breast Cancer Recommendation Statement on Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer.

    News:

    USPSTF Calls for More BRCA Screening.

    Patient Page:

    Should I Be Tested for BRCA Mutations?

    Audio Interview, CME Activity: USPSTF Recommendation: Assessment, Counseling, and Testing for BRCA-Related Cancer. (JAMA)

    Press: USPSTF Recommendations on BRCA Mutation Testing. (Medscape Oncology)

    • Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer in Women: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.
    • Nelson HD, Pappas M, Cantor A, Haney E, Holmes R.
    • JAMA. 2019 Aug 20;322(7):666-685. doi: 10.1001/jama.2019.8430.

    Guidelines:

    Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer: US Preventive Services Task Force Recommendation Statement.

    Guidelines:

    Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA1/2-Related Cancer in Women: A Systematic Review for the U.S. Preventive Services Task Force [Internet].

    • Should I Be Tested for BRCA Mutations?
    • Jin J.
    • JAMA. 2019 Aug 20;322(7):702. doi: 10.1001/jama.2019.11251.

    Guidelines:

    Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer: US Preventive Services Task Force Recommendation Statement.

    • USPSTF Recommendation: Assessment, Counseling, and Testing for BRCA-Related Cancer.
    • Mangione CM.
    • JAMA. 2019 Aug 20.

    Guidelines:

    Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer: US Preventive Services Task Force Recommendation Statement.

    • Management of ovarian cancer risk in women with BRCA1/2 pathogenic variants.
    • Walker M, Jacobson M, Sobel M.
    • CMAJ. 2019 Aug 12;191(32):E886-E893. doi: 10.1503/cmaj.190281.
    • Peritoneal involvement by salpingoliths clinical significance and cytological challenges of interpretation.
    • El Hussein S, Guerrero D, Khader SN.
    • Diagn Cytopathol. 2019 Aug 7. doi: 10.1002/dc.24299. [Epub ahead of print]
    • Case report
    • Changes in Bone Mineral Density After Prophylactic Bilateral Salpingo-Oophorectomy in Carriers of a BRCA Mutation.
    • Kotsopoulos J, Hall E, Finch A, Hu H, Murphy J, Rosen B, Narod SA, Cheung AM.
    • JAMA Netw Open. 2019 Aug 2;2(8):e198420. doi: 10.1001/jamanetworkopen.2019.8420.
    • Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA1/2-Related Cancer in Women: A Systematic Review for the U.S. Preventive Services Task Force [Internet].
    • Nelson HD, Pappas M, Cantor A, Haney E, Holmes R, Stillman L.
    • Rockville (MD): Agency for Healthcare Research and Quality (US); 2019 Aug. Report No.: 19-05251-EF-1. U.S. Preventive Services Task Force Evidence Syntheses, formerly Systematic Evidence Reviews.

    Guidelines:

    Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer: US Preventive Services Task Force Recommendation Statement.

    Guidelines:

    Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer in Women: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.

    • Screening and surgical prophylaxis for hereditary cancer syndromes with high risk of endometrial and ovarian cancer.
    • Bercow AS, Eisenhauer EL.
    • J Surg Oncol. 2019 Jul 29. doi: 10.1002/jso.25645. [Epub ahead of print]
    • Review
    • Risk-Reducing Bilateral Salpingo-Oophorectomy for BRCA Mutation Carriers and Hormonal Replacement Therapy: If It Should Rain, Better a Drizzle than a Storm.
    • Gasparri ML, Taghavi K, Fiacco E, Zuber V, Di Micco R, Gazzetta G, Valentini A, Mueller MD, Papadia A, Gentilini OD.
    • Medicina (Kaunas). 2019 Jul 29;55(8). pii: E415. doi: 10.3390/medicina55080415.
    • Laparoscopic intra-operative ultrasound-guided bilateral salpingo-oophorectomy in a BRCA2 mutated patient.
    • Bruno M, De Blasis I, Marinucci B, Testa AC, Scambia G, Fagotti A.
    • Int J Gynecol Cancer. 2019 Jul 17. pii: ijgc-2019-000530. doi: 10.1136/ijgc-2019-000530. [Epub ahead of print]
    • Contemporary management of adnexa at the time of benign hysterectomy: a review of the literature.
    • Tamhane N, Imudia AN, Mikhail E.
    • J Obstet Gynaecol. 2019 Jul 13:1-7. doi: 10.1080/01443615.2019.1581747. [Epub ahead of print]
    • Review
    • Ovarian remnant syndrome in an aromatase inhibitor-treated patient with BRCA2 mutation following bilateral oophorectomy.
    • Wei M, Maurer KA, Henry NL.
    • Breast J. 2019 Jul 4. doi: 10.1111/tbj.13454. [Epub ahead of print]
    • Case report
    • How Safe Is Hormone Replacement Therapy After Risk-Reducing Salpingo-oophorectomy in Women With BRCA Mutations?
    • Markman M.
    • Medscape Oncology. 2019 Jun 14.

    Original research:

    Hormone replacement therapy after risk reducing salpingo-oophorectomy in patients with BRCA1 or BRCA2 mutations; a systematic review of risks and benefits.

    • [Recommendations for Preventive Care for Women with Rare Genetic Cause of Breast and Ovarian Cancer.]
    • Foretová L, Navrátilová M, Svoboda M, Vašíčková P, Sťahlová EH, Házová J, Kleiblová P, Kleibl Z, Macháčková E, Palácová M, Petráková K.
    • Klin Onkol. 2019 Summer;32(Supplementum2):6-13. doi: 10.14735/amko2019S6.
    • Risk-reducing early salpingectomy and delayed oophorectomy as a two-staged alternative for primary prevention of ovarian cancer in women at increased risk: a commentary.
    • Gaba F, Piek J, Menon U, Manchanda R.
    • BJOG. 2019 Jun;126(7):831-839. doi: 10.1111/1471-0528.15651. Epub 2019 Mar 14.
    • Commentary
    • Women's health 2019: Osteoporosis, breast cancer, contraception, and hormone therapy.
    • Moreno AC, Sahni SK, Smith TL, Batur P.
    • Cleve Clin J Med. 2019 Jun;86(6):400-406. doi: 10.3949/ccjm.86a.18130.
    • Concurrent hysterectomy at the tine of risk-reducing surgery for patients with BRCA mutations.
    • Gordhandas S, Ruiz MP, Talukdar N, Holcomb KM, Freya MK, Chapman-Davis E, Kahn RM.
    • Gynecol Oncol. 2019 Jun;153(3):e12-e13. doi: 10.1016/j.ygyno.2019.03.134.
    • Conference abstract
    • Long-term morbidity and health after early menopause due to oophorectomy in women at increased risk of ovarian cancer: rationale and design of the harmony study.
    • Terra L, Hooning MJ, Heemskerk-Gerritsen BAM, Maas AHEM, van Leeuwen FE, HARMOny investigators.
    • Maturitas. 2019 Jun;124:159-160. doi: 10.1016/j.maturitas.2019.04.136.
    • Conference abstract, Review
    • Challenges in Managing Patients with Hereditary Cancer at Gynecological Services.
    • Ueda M, Tsubamoto H, Kashima-Morii M, Torii Y, Kamihigashi M, Wakimoto Y, Nakagomi N, Hashimoto-Tamaoki T, Sawai H, Shibahara H.
    • Obstet Gynecol Int. 2019 May 27;2019:4365754. doi: 10.1155/2019/4365754. eCollection 2019.
    • Development of Peritoneal Carcinoma in women diagnosed with Serous Tubal Intraepithelial Carcinoma (STIC) following Risk-Reducing Salpingo-Oophorectomy (RRSO).
    • Stanciu PI, Ind TEJ, Barton DPJ, Butler JB, Vroobel KM, Attygalle AD, Nobbenhuis MAE.
    • J Ovarian Res. 2019 May 25;12(1):50. doi: 10.1186/s13048-019-0525-1.
    • Opportunistic Salpingectomy at the Time of Urogynecologic Surgery: Why, in Whom, and How?
    • Catanzarite T, Eskander RN.
    • Female Pelvic Med Reconstr Surg. 2019 May 22. doi: 10.1097/SPV.0000000000000741. [Epub ahead of print]
    • Review
    • Clinical background and outcomes of risk-reducing salpingo-oophorectomy for hereditary breast and ovarian cancers in Japan.
    • Nomura H, Sekine M, Yokoyama S, Arai M, Enomoto T, Takeshima N, Nakamura S.
    • Int J Clin Oncol. 2019 May 4. doi: 10.1007/s10147-019-01456-4. [Epub ahead of print]
    • Retrospective study of a 16 year cohort of BRCA1 and BRCA2 carriers presenting for RRSO: Prevalence of invasive and in-situ carcinoma, with follow-up.
    • Blok F, Dasgupta S, Dinjens WNM, Roes EM, van Beekhuizen HJ, Ewing-Graham PC.
    • Gynecol Oncol. 2019 May;153(2):326-334. doi: 10.1016/j.ygyno.2019.03.003. Epub 2019 Mar 18.
    • An Alternate Diagnostic Algorithm for the Diagnosis of Intraepithelial Fallopian Tube Lesions.
    • Perrone ME, Reder NP, Agoff SN, Garcia RL, Agnew KJ, Norquist BM, Pennington KP, Swisher EM, Kilgore MR.
    • Int J Gynecol Pathol. 2019 Apr 24. doi: 10.1097/PGP.0000000000000604. [Epub ahead of print]
    • Analysis of Outcomes in Patients With BRCA1/2 Breast Cancer Mutations Treated With Accelerated Partial Breast Irradiation (APBI).
    • Ahmed F, Christos PJ, Singh P, Parashar B, Wernicke AG.
    • Am J Clin Oncol. 2019 Apr 9. doi: 10.1097/COC.0000000000000542. [Epub ahead of print]
    • Hormone replacement therapy after risk reducing salpingo-oophorectomy in patients with BRCA1 or BRCA2
    • Gordhandas S, Norquist BM, Pennington KP, Yung RL, Laya MB, Swisher EM.
    • Gynecol Oncol. 2019 Apr;153(1):192-200. doi: 10.1016/j.ygyno.2018.12.014. Epub 2019 Jan 17.
    • Review

    Commentary: How Safe Is Hormone Replacement Therapy After Risk-Reducing Salpingo-oophorectomy in Women With BRCA Mutations? (Medscape Oncology)

    • Safety of hormone replacement therapy following risk-reducing salpingo-oophorectomy: systematic review of literature and guidelines.
    • Vermeulen RFM, Korse CM, Kenter GG, Brood-van Zanten MMA, Beurden MV.
    • Climacteric. 2019 Mar 25:1-9. doi: 10.1080/13697137.2019.1582622. [Epub ahead of print]
    • Review
    • Surgery to Reduce Ovarian Cancer Risk — One Step or Two?
    • Harrison P
    • Medscape. Medscape Oncology. 2019 Mar 25.
    • Selected features of breast and peritoneal cancers diagnosed in BRCA1 carriers after risk-reducing salpingo-oophorectomy.
    • Menkiszak J, Chudecka-Głaz A, Cymbaluk-Płoska A, Celewicz A, Kojs Z, Szajda M, Świniarska M, Bedner R, Jurczak A, Celewicz M, Cieszyńska M, Lubiński J, Gronwald J.
    • Hered Cancer Clin Pract. 2019 Mar 14;17:10. doi: 10.1186/s13053-019-0109-5. eCollection 2019.
    • Risk-Reducing Oophorectomy and Breast Cancer Risk Across the Spectrum of Familial Risk.
    • Terry MB, Daly MB, Phillips KA, Ma X, Zeinomar N, Leoce N, Dite GS, MacInnis RJ, Chung WK, Knight JA, Southey MC, Milne RL, Goldgar D, Giles GG, Weideman PC, Glendon G, Buchsbaum R, Andrulis IL, John EM, Buys SS, Hopper JL.
    • J Natl Cancer Inst. 2019 Mar 1;111(3):331-334. doi: 10.1093/jnci/djy182.

    Press: Oophorectomy to Reduce Ovarian-cancer Risk Not Tied to Breast-cancer Risk. (Medscape Oncology)

    • BRCA mutation testing for first-degree relatives of women with high-grade serous ovarian cancer.
    • Kwon JS, Tinker AV, Hanley GE, Pansegrau G, Sun S, Carey MS, Schrader I.
    • Gynecol Oncol. 2019 Mar;152(3):459-464. doi: 10.1016/j.ygyno.2018.10.014.
    • High-Grade Serous Ovarian Cancer: Basic Sciences, Clinical and Therapeutic Standpoints.
    • Lisio MA, Fu L, Goyeneche A, Gao ZH, Telleria C.
    • Int J Mol Sci. 2019 Feb 22;20(4). pii: E952. doi: 10.3390/ijms20040952.
    • Evaluation of screening and risk-reducing surgery for women followed in a high-risk breast/ovarian cancer clinic: it is all about the tubes in BRCA mutation carriers.
    • Stewart ME, Knisely AT, Sullivan MW, Ring KL, Modesitt SC.
    • Gynecol Oncol Rep. 2019 Feb 1;28:18-22. doi: 10.1016/j.gore.2019.01.010. eCollection 2019 May.
    • Risk Reduction and Survival Benefit of Risk-Reducing Salpingo-oophorectomy in Hereditary Breast Cancer: Meta-analysis and Systematic Review.
    • Xiao YL, Wang K, Liu Q, Li J, Zhang X, Li HY.
    • Clin Breast Cancer. 2019 Feb;19(1):e48-e65. doi: 10.1016/j.clbc.2018.09.011. Epub 2018 Oct 4.
    • Perioperative Management of Women Undergoing Risk-reducing Surgery for Hereditary Breast and Ovarian Cancer.
    • AlHilli MM, Al-Hilli Z.
    • J Minim Invasive Gynecol. 2019 Feb;26(2):253-265. doi: 10.1016/j.jmig.2018.09.767. Epub 2018 Sep 19.
    • Risk factors for sexual dysfunction in BRCA mutation carriers after risk-reducing salpingo-oophorectomy.
    • Chan JL, Senapati S, Johnson LNC, DiGiovanni L, Voong C, Butts SF, Domchek SM.
    • Menopause. 2019 Feb;26(2):132-139. doi: 10.1097/GME.0000000000001176.
    • Targeted surgical prevention of epithelial ovarian cancer is cost effective and saves money in BRCA mutation carrying family members of women with epithelial ovarian cancer. A Canadian model.
    • Hoskins P, Eccleston A, Hurry M, Dyer M.
    • Gynecol Oncol. 2019 Jan 28. pii: S0090-8258(19)30061-7. doi: 10.1016/j.ygyno.2019.01.018. [Epub ahead of print]
    • Risk-Reducing Mastectomy in BRCA1 and BRCA2 Mutation Carriers: A Complex Discussion.
    • Domchek SM.
    • JAMA. 2019 Jan 1;321(1):27. doi: 10.1001/jama.2018.18942.
    • Review, Commentary
    • Association of Bilateral Salpingo-Oophorectomy Before Menopause Onset With Medial Temporal Lobe Neurodegeneration.
    • Zeydan B, Tosakulwong N, Schwarz CG, Senjem ML, Gunter JL, Reid RI, Gazzuola Rocca L, Lesnick TG, Smith CY, Bailey KR, Lowe VJ, Roberts RO, Jack CR Jr, Petersen RC, Miller VM, Mielke MM, Rocca WA, Kantarci K.
    • JAMA Neurol. 2019 Jan 1;76(1):95-100. doi: 10.1001/jamaneurol.2018.3057.
    • Cholesterol profile in women with premature menopause after risk reducing salpingo-oophorectomy.
    • Teixeira N, Mourits MJ, Oosterwijk JC, Fakkert IE, Absalom AR, Bakker SJL, van der Meer P, de Bock GH.
    • Fam Cancer. 2019 Jan;18(1):19-27. doi: 10.1007/s10689-018-0091-5.
    • Effects of bilateral salpingo-oophorectomy on menopausal symptoms and sexual functioning among women with a BRCA1 or BRCA2 mutation.
    • Hall E, Finch A, Jacobson M, Rosen B, Metcalfe K, Sun P, Narod SA, Kotsopoulos J.
    • Gynecol Oncol. 2019 Jan;152(1):145-150. doi: 10.1016/j.ygyno.2018.10.040. Epub 2018 Nov 7.
    • Does anti-Müllerian hormone predict change in menopausal symptoms following risk-reducing salpingo-oophorectomy? A prospective observational study.
    • Vermeulen RFM, van Beurden M, Gaarenstroom KN, Teunis T, Kieffer JM, Aaronson NK, Kenter GG, Korse CM.
    • Climacteric. 2018 Dec;21(6):574-580. doi: 10.1080/13697137.2018.1512965. Epub 2018 Oct 8.
    • Risk of cardiovascular disease in women with BRCA1 and BRCA2 mutations.
    • Powell CB, Alabaster A, Armstrong MA, Stoller N, Raine-Bennett T.
    • Gynecol Oncol. 2018 Dec;151(3):489-493. doi: 10.1016/j.ygyno.2018.10.010. Epub 2018 Oct 10.
    • An Unusual Adenomatoid Tumor of Fimbria with Pronounced Psammoma Bodies in a BRCA Positive Patient as a Pitfall for Carcinoma on Frozen Section.
    • Lee CM, Moh M, Sullivan PS, Moatamed NA.
    • Case Rep Pathol. 2018 Nov 21;2018:8148147. doi: 10.1155/2018/8148147. eCollection 2018.
    • Cancer Risk-Reducing Opportunities in Gynecologic Surgery.
    • Piszczek C, Ma J, Gould CH, Tseng P.
    • J Minim Invasive Gynecol. 2018 Nov - Dec;25(7):1179-1193. doi: 10.1016/j.jmig.2017.10.025. Epub 2017 Oct 31.
    • Review
    • Hysterectomy at the time of risk-reducing surgery in BRCA carriers.
    • Nair N, Schwartz M, Guzzardi L, Durlester N, Pan S, Overbey J, Chuang L.
    • Gynecol Oncol Rep. 2018 Oct 6;26:71-74. doi: 10.1016/j.gore.2018.10.003. eCollection 2018 Nov.
    • Risk-Reducing Options for Women with a Hereditary Breast Cancer Predisposition.
    • Jatoi I.
    • Eur J Breast Health. 2018 Oct 1;14(4):189-193. doi: 10.5152/ejbh.2018.4324. eCollection 2018 Oct.

    Letter, Review:

    What The Surgeons Should Know About The Bilateral Prophylactic Mastectomy in BRCA Mutation Carriers.

    • Surgical prevention strategies in ovarian cancer.
    • Mallen A, Soong TR, Townsend MK, Wenham RM, Crum CP, Tworoger SS.
    • Gynecol Oncol. 2018 Oct;151(1):166-175. doi: 10.1016/j.ygyno.2018.08.005. Epub 2018 Aug 4.
    • Review
    • Hormone therapy and breast cancer risk after ovary removal in women with a BRCA1 mutation.
    • [No author given]
    • FORCE. XRAYS. 2018 Sep 7.

    Hormone Replacement Therapy After Oophorectomy and Breast Cancer Risk Among BRCA1 Mutation Carriers.

    • Surgery for BRCA, TP53 and PALB2: a literature review.
    • Song CV, Teo SH, Taib NA, Yip CH.
    • Ecancermedicalscience. 2018 Aug 29;12:863. doi: 10.3332/ecancer.2018.863. eCollection 2018.
    • Risk-reducing bilateral salpingo-oophorectomy in women with BRCA1 or BRCA2 mutations.
    • Eleje GU, Eke AC, Ezebialu IU, Ikechebelu JI, Ugwu EO, Okonkwo OO.
    • Cochrane Database Syst Rev. 2018 Aug 24;8:CD012464. doi: 10.1002/14651858.CD012464.pub2.
    • Meta-Analysis, Review
    • Hormone Replacement Therapy After Oophorectomy and Breast Cancer Risk Among BRCA1 Mutation Carriers.
    • Kotsopoulos J, Gronwald J, Karlan BY, Huzarski T, Tung N, Moller P, Armel S, Lynch HT, Senter L, Eisen A, Singer CF, Foulkes WD, Jacobson MR, Sun P, Lubinski J, Narod SA; Hereditary Breast Cancer Clinical Study Group.
    • JAMA Oncol. 2018 Aug 1;4(8):1059-1065. doi: 10.1001/jamaoncol.2018.0211.

    Research News: Hormone therapy and breast cancer risk after ovary removal in women with a BRCA1 mutation. (FORCE, XRAYS)

    Commentary, Video: Menopausal Hormone Therapy and Risk for Breast Cancer in BRCA1 Mutation Carriers. (Medscape)

    • Concurrent risk-reduction surgery in patients with increased lifetime risk for breast and ovarian cancer: an analysis of the National Surgical Quality Improvement Program (NSQIP) database.
    • Elmi M, Azin A, Elnahas A, McCready DR, Cil TD.
    • Breast Cancer Res Treat. 2018 Aug;171(1):217-223. doi: 10.1007/s10549-018-4818-7. Epub 2018 May 14.
    • Outcome and Prognostic Impact of Surgical Staging in Serous Tubal Intraepithelial Carcinoma: A Cohort Study and Systematic Review.
    • Van der Hoeven NMA, Van Wijk K, Bonfrer SE, Beltman JJ, Louwe LA, De Kroon CD, Van Asperen CJ, Gaarenstroom KN.
    • Clin Oncol (R Coll Radiol). 2018 Aug;30(8):463-471. doi: 10.1016/j.clon.2018.03.036. Epub 2018 Apr 22.
    • Reducing the Risk of Gynecologic Cancer in Hereditary Breast Ovarian Cancer Syndrome Mutation Carriers: Moral Dilemmas and the Principle of Double Effect.
    • Casey MJ, Salzman TA.
    • Linacre Q. 2018 Aug;85(3):225-240. doi: 10.1177/0024363918788340. Epub 2018 Jul 20.
    • Mortality and Risk of Cancer After Prophylactic Bilateral Oophorectomy in Women With a Family History of Cancer.
    • Abildgaard J, Ahlström MG, Daugaard G, Nielsen DL, Tønnes Pedersen A, Lindegaard B, Obel N.
    • JNCI Cancer Spectrum. 2018 Jul 1;2(3):pky034. doi: 10.1093/jncics/pky034.
    • Bilateral salpingectomy with delayed oophorectomy for ovarian cancer risk reduction: A pilot study in women with BRCA1/2 mutations.
    • Nebgen DR, Hurteau J, Holman LL, Bradford A, Munsell MF, Soletsky BR, Sun CC, Chisholm GB, Lu KH.
    • Gynecol Oncol. 2018 Jul;150(1):79-84. doi: 10.1016/j.ygyno.2018.04.564. Epub 2018 May 4.
    • Age-specific ovarian cancer risks among women with a BRCA1 or BRCA2 mutation.
    • Kotsopoulos J, Gronwald J, Karlan B, Rosen B, Huzarski T, Moller P, Lynch HT, Singer CF, Senter L, Neuhausen SL, Tung N, Eisen A, Foulkes WD, Ainsworth P, Sun P, Lubinski J, Narod SA; Hereditary Ovarian Cancer Clinical Study Group.
    • Gynecol Oncol. 2018 Jul;150(1):85-91. doi: 10.1016/j.ygyno.2018.05.011. Epub 2018 May 21.
    • Intra-operative evaluation of prophylactic hysterectomy and salpingo-oophorectomy specimens in hereditary gynaecological cancer syndromes.
    • Wong S, Ratner E, Buza N.
    • Histopathology. 2018 Jul;73(1):109-123. doi: 10.1111/his.13503. Epub 2018 Apr 16.
    • Hormone Levels and Sexual Functioning After Risk-Reducing Salpingo-Oophorectomy.
    • Johansen N, Liavaag AH, Mørkrid L, Michelsen TM.
    • Sex Med. 2018 Jun;6(2):143-153. doi: 10.1016/j.esxm.2018.02.002. Epub 2018 Apr 7.
    • Severity and duration of menopausal symptoms after risk-reducing salpingo-oophorectomy.
    • Stuursma A, van Driel CMG, Wessels NJ, de Bock GH, Mourits MJE.
    • Maturitas. 2018 May;111:69-76. doi: 10.1016/j.maturitas.2018.01.012. Epub 2018 Jan 13.
    • Ovarian Cancer Prevention and Screening.
    • Menon U, Karpinskyj C, Gentry-Maharaj A.
    • Obstet Gynecol. 2018 May;131(5):909-927. doi: 10.1097/AOG.0000000000002580.
    • Review
    • Prophylactic salpingo-oophorectomy & surgical menopause for inherited risks of cancer: the need to identify biomarkers to assess the theoretical risk of premature coronary artery disease.
    • Batulan Z, Maarouf N, Shrivastava V, O'Brien E.
    • Womens Midlife Health. 2018 Apr 27;4:7. doi: 10.1186/s40695-018-0037-y. eCollection 2018.
    • Cost-effectiveness of different strategies to prevent breast and ovarian cancer in German women with a BRCA 1 or 2 mutation.
    • Müller D, Danner M, Rhiem K, Stollenwerk B, Engel C, Rasche L, Borsi L, Schmutzler R, Stock S.
    • Eur J Health Econ. 2018 Apr;19(3):341-353. doi: 10.1007/s10198-017-0887-5. Epub 2017 Apr 5.
    • Does oophorectomy reduce breast cancer mortality for BRCA mutation carriers after breast cancer?
    • Jacobson M, Narod SA.
    • Expert Rev Anticancer Ther. 2018 Apr;18(4):305-306. doi: 10.1080/14737140.2018.1438891. Epub 2018 Feb 16.
    • [Cost-effectiveness of risk-reducing salpingo-oophorectomy in cases of BRCA1 gene mutation in Colombia].
    • González-Mariño MA.
    • Rev Salud Publica (Bogota). 2018 Mar-Apr;20(2):232-236. doi: 10.15446/rsap.V20n2.64866.
    • Cost-effectiveness of surveillance and prevention strategies in BRCA1/2 mutation carriers.
    • Yamauchi H, Nakagawa C, Kobayashi M, Kobayashi Y, Mano T, Nakamura S, Arai M.
    • Breast Cancer. 2018 Mar;25(2):141-150. doi: 10.1007/s12282-017-0803-y. Epub 2017 Oct 10.
    • Commercially Available Lifestyle Modification Program Decreases Inflammatory Biomarkers in BRCA1/2+ Breast Cancer Survivors.
    • Sturgeon KM, Foo W, Schmitz KH/
    • Cancer Epidemiol Biomarkers Prev. 2018 Mar;27(3):357-357. doi: 10.1158/1055-9965.EPI-18-0063.
    • Conference abstract
    • Processing of fallopian tube, ovary, and endometrial surgical pathology specimens: A survey of U.S. laboratory practices.
    • Samimi G, Trabert B, Duggan MA, Robinson JL, Coa KI, Waibel E, Garcia E, Minasian LM, Sherman ME.
    • Gynecol Oncol. 2018 Mar;148(3):515-520. doi: 10.1016/j.ygyno.2018.01.016.
    • Recommendations and Choices for BRCA Mutation Carriers at Risk for Ovarian Cancer: A Complicated Decision.
    • Lewis KE, Lu KH, Klimczak AM, Mok SC.
    • Cancers (Basel). 2018 Feb 21;10(2). pii: E57. doi: 10.3390/cancers10020057.
    • Breast tissue density change after oophorectomy in BRCA mutation carrier patients using visual and volumetric analysis.
    • Lecler A, Dunant A, Delaloge S, Wehrer D, Moussa T, Caron O, Balleyguier C.
    • Br J Radiol. 2018 Feb;91(1083):20170163. doi: 10.1259/bjr.20170163. Epub 2018 Jan 5.
    • Management of hereditary breast and ovarian cancer.
    • Yamauchi H, Takei J.
    • Int J Clin Oncol. 2018 Feb;23(1):45-51. doi: 10.1007/s10147-017-1208-9. Epub 2017 Nov 28.
    • Review
    • Setting the Threshold for Surgical Prevention in Women at Increased Risk of Ovarian Cancer.
    • Manchanda R, Menon U.
    • Int J Gynecol Cancer. 2018 Jan;28(1):34-42. doi: 10.1097/IGC.0000000000001147.
    • Vaginal Salpingectomy Techniques in the Presence of Ovarian Conservation.
    • Cornella JL.
    • J Minim Invasive Gynecol. 2018 Jan;25(1):16. doi: 10.1016/j.jmig.2017.06.012. Epub 2017 Jun 21.
    • Surgical Findings and Outcomes in Premenopausal Breast Cancer Patients Undergoing Oophorectomy: A Multicenter Review From the Society of Gynecologic Surgeons Fellows Pelvic Research Network.
    • Harvey LFB, Abramson VG, Alvarez J, DeStephano C, Hur HC, Lee K, Mattingly P, Park B, Piszczek C, Seifi F, Stuparich M, Yunker A.
    • J Minim Invasive Gynecol. 2018 Jan;25(1):111-115. doi: 10.1016/j.jmig.2017.08.643. Epub 2017 Aug 15.
    • A salpingeal carcinoma revealed after prophylactic salpingoophorectomy in an asymptomatic BRCA1 carrier with breast malignancy.
    • Giannos A, Stavrou S, Douskos A, Drakakis P, Loutradis D.
    • Int J Surg Case Rep. 2018;52:107-110. doi: 10.1016/j.ijscr.2018.10.014. Epub 2018 Oct 12.
    • [Does ovarian cancer start in the fallopian tubes? Possible implications for preventive adnexal removal].
    • Steenbeek MP, Bulten J, Hoogerbrugge N, Massuger LFAG, Pijnenborg JMA, de Hullu JA.
    • Ned Tijdschr Geneeskd. 2018;162(0):D2337.
    • Case report, [Article in Dutch]
    • "Best practices in risk reducing bilateral salpingo-oophorectomy: the influence of surgical specialty".
    • Malacarne DR, Boyd LR, Long Y, Blank SV.
    • World J Surg Oncol. 2017 Dec 11;15(1):218. doi: 10.1186/s12957-017-1282-5.
    • Cells of origin of ovarian cancer: ovarian surface epithelium or fallopian tube?
    • Klotz DM, Wimberger P.
    • Arch Gynecol Obstet. 2017 Dec;296(6):1055-1062. doi: 10.1007/s00404-017-4529-z. Epub 2017 Sep 23.
    • Review
    • Prophylactic Surgery: For Whom, When and How?
    • Mau C, Untch M.
    • Breast Care (Basel). 2017 Dec;12(6):379-384. doi: 10.1159/000485830. Epub 2017 Dec 13.
    • Risk-reducing salpingo-oophorectomy in BRCA1 and BRCA2 mutated patients: An evidence-based approach on what women should know.
    • De Felice F, Marchetti C, Boccia SM, Romito A, Sassu CM, Porpora MG, Muzii L, Tombolini V, Benedetti Panici P.
    • Cancer Treat Rev. 2017 Dec;61:1-5. doi: 10.1016/j.ctrv.2017.09.005. Epub 2017 Sep 28.
    • Review
    • Sexual Health Is Paramount in the Counseling of Women at Risk for Breast or Ovarian Cancer Undergoing Risk-Reducing Surgery.
    • Rullo JE, Pruthi S.
    • J Natl Compr Canc Netw. 2017 Nov 1;15(11):1297. doi: 10.6004/jnccn.2017.7016.
    • Commentary
    • Regarding "The Role of Routine Peritoneal and Omental Biopsies at Risk-reducing Salpingo-oophorectomy".
    • Bogani G, Signorelli M, Chiappa V, Carcangiu ML, Martinelli F, Paolini B, Leone Roberti Maggiore U, Gennaro M, Borghi C, Scaffa C, Ditto A, Lorusso D, Raspagliesi F.
    • J Minim Invasive Gynecol. 2017 Nov - Dec;24(7):1243-1244. doi: 10.1016/j.jmig.2017.05.020. Epub 2017 Jun 23.
    • Letter

    Letter:

    Author's Reply.

    • Missed therapeutic and prevention opportunities in women with BRCA-mutated epithelial ovarian cancer and their families due to low referral rates for genetic counseling and BRCA testing: A review of the literature.
    • Hoskins PJ, Gotlieb WH.
    • CA Cancer J Clin. 2017 Nov;67(6):493-506. doi: 10.3322/caac.21408. Epub 2017 Sep 7.
    • BRCA and lynch syndrome-associated ovarian cancers behave differently.
    • Ryan NAJ, Bolton J, McVey RJ, Evans DG, Crosbie EJ.
    • Gynecol Oncol Rep. 2017 Nov 22;22:108-109. doi: 10.1016/j.gore.2017.11.007. eCollection 2017 Nov.

    Pathological features and clinical behavior of Lynch syndrome-associated ovarian cancer.

    Letter: Ovarian carcinoma histotype in Lynch syndrome. (Gynecologic Oncology Reports)

    • Ovarian Cancer Prevention, Screening, and Early Detection: Report From the 11th Biennial Ovarian Cancer Research Symposium.
    • Chien J, Poole EM.
    • Int J Gynecol Cancer. 2017 Nov;27(9S Suppl 5):S20-S22. doi: 10.1097/IGC.0000000000001118.
    • Conference report
    • RE: Bilateral Oophorectomy and Breast Cancer Risk in BRCA1 and BRCA2 Mutation Carriers.
    • Nolan E, Vaillant F, Visvader JE, Lindeman GJ.
    • J Natl Cancer Inst. 2017 Oct 1;109(10). doi: 10.1093/jnci/djx038.
    • Letter

    Letter, Reply:

    Response.

    • The Evolution of and Evidence for Opportunistic Salpingectomy.
    • Dilley SE, Straughn JM Jr, Leath CA 3rd.
    • Obstet Gynecol. 2017 Oct;130(4):814-824. doi: 10.1097/AOG.0000000000002243.
    • Review
    • Dynamic real-time in vivo confocal laser endomicroscopy of the fallopian tube during laparoscopy in the prevention of ovarian cancer.
    • Chene G, Chauvy L, Buenerd A, Moret S, Nadaud B, Chabert P, Lamblin G.
    • Eur J Obstet Gynecol Reprod Biol. 2017 Sep;216:18-23. doi: 10.1016/j.ejogrb.2017.07.002. Epub 2017 Jul 5.
    • LEF1 is preferentially expressed in the tubal-peritoneal junctions and is a reliable marker of tubal intraepithelial lesions.
    • Schmoeckel E, Odai-Afotey AA, Schleißheimer M, Rottmann M, Flesken-Nikitin A, Ellenson LH, Kirchner T, Mayr D, Nikitin AY.
    • Mod Pathol. 2017 Sep;30(9):1241-1250. doi: 10.1038/modpathol.2017.53. Epub 2017 Jun 30.
    • Opportunistic Salpingectomy as an Ovarian Cancer Primary Prevention Strategy.
    • Balsarkar G.
    • J Obstet Gynaecol India. 2017 Aug;67(4):243-246. doi: 10.1007/s13224-017-0998-z. Epub 2017 May 11.
    • Risk Reduction Strategies in Breast Cancer Prevention.
    • Costa M, Saldanha P.
    • Eur J Breast Health. 2017 Jul 1;13(3):103-112. doi: 10.5152/ejbh.2017.3583. eCollection 2017 Jul.
    • Impact of risk-reducing salpingo-oophorectomy in premenopausal women.
    • Vermeulen RFM, Beurden MV, Korse CM, Kenter GG.
    • Climacteric. 2017 Jun;20(3):212-221. doi: 10.1080/13697137.2017.1285879. Epub 2017 Mar 2.
    • Mortality reduction and cost-effectiveness of performing hysterectomy at the time of risk-reducing salpingo-oophorectomy for prophylaxis against serous/serous-like uterine cancers in BRCA1 mutation carriers.
    • Havrilesky LJ, Moss HA, Chino J, Myers ER, Kauff ND.
    • Gynecol Oncol. 2017 Jun;145(3):549-554. doi: 10.1016/j.ygyno.2017.03.025. Epub 2017 Apr 6.
    • Practice Patterns of Hereditary Ovarian Cancer Management in Korea.
    • Choi MC, Lim MC, Lee M, Kim MK, Suh DH, Song YJ, Kim TJ, Chang SJ, Kim JW.
    • Int J Gynecol Cancer. 2017 Jun;27(5):895-899. doi: 10.1097/IGC.0000000000000964.
    • No. 344-Opportunistic Salpingectomy and Other Methods of Risk Reduction for Ovarian/Fallopian Tube/Peritoneal Cancer in the General Population.
    • Salvador S, Scott S, Francis JA, Agrawal A, Giede C.
    • J Obstet Gynaecol Can. 2017 Jun;39(6):480-493. doi: 10.1016/j.jogc.2016.12.005.
    • Practice Guideline, Review

    Practice Guideline, Review, [Article in French]:

    No 344-Salpingectomie opportuniste et autres méthodes pour réduire le risque de cancer de l'ovaire, de la trompe de Fallope et du péritoine dans la population générale.

    • No 344-Salpingectomie opportuniste et autres méthodes pour réduire le risque de cancer de l'ovaire, de la trompe de Fallope et du péritoine dans la population générale.
    • Salvador S, Scott S, Francis JA, Agrawal A, Giede C.
    • J Obstet Gynaecol Can. 2017 Jun;39(6):494-508. doi: 10.1016/j.jogc.2017.03.121.
    • Practice Guideline, Review, [Article in French]

    Practice Guideline, Review, English Abstract:

    No. 344-Opportunistic Salpingectomy and Other Methods of Risk Reduction for Ovarian/Fallopian Tube/Peritoneal Cancer in the General Population.

    • Interventions to reduce the risk of ovarian and fallopian tube cancer: A European Menopause and Andropause Society Postition Statement.
    • Pérez-López FR, Ceausu I, Depypere H, Kehoe S, Lambrinoudaki I, Mueck A, Senturk LM, Simoncini T, Stevenson JC, Stute P, Rees M.
    • Maturitas. 2017 Jun;100:86-91. doi: 10.1016/j.maturitas.2017.03.003. Epub 2017 Mar 15.
    • Practice Patterns of Hereditary Ovarian Cancer Management in Korea.
    • Choi MC, Lim MC, Lee M, Kim MK, Suh DH, Song YJ, Kim TJ, Chang SJ, Kim JW.
    • Int J Gynecol Cancer. 2017 May 12. doi: 10.1097/IGC.0000000000000964. [Epub ahead of print]
    • Ovarian carcinoma histotype in Lynch syndrome.
    • Gilks CB, Clarke BA, Foulkes WD.
    • Gynecol Oncol Rep. 2017 Mar 16;20:140-141. doi: 10.1016/j.gore.2017.03.009. eCollection 2017 May.

    Pathological features and clinical behavior of Lynch syndrome-associated ovarian cancer.

    Letter:

    BRCA and lynch syndrome-associated ovarian cancers behave differently.

    • Cost-effectiveness of risk-reducing surgeries in preventing hereditary breast and ovarian cancer.
    • Schrauder MG, Brunel-Geuder L, Häberle L, Wunderle M, Hoyer J, Reis A, Schulz-Wendtland R, Beckmann MW, Lux MP.
    • Breast. 2017 Apr;32:186-191. doi: 10.1016/j.breast.2017.02.008. Epub 2017 Feb 17.
    • Risk-Reducing Strategies for Ovarian Cancer in BRCA Mutation Carriers: A Balancing Act.
    • Tschernichovsky R, Goodman A.
    • Oncologist. 2017 Apr;22(4):450-459. doi: 10.1634/theoncologist.2016-0444. Epub 2017 Mar 17.
    • Early-onset primary peritoneal carcinoma from atypical cells after risk-reducing salpingo-oophorectomy for BRCA2 mutation carrier: a case report.
    • Shimizu H, Ishikawa T, Iitsuka C, Homma M, Takimoto M, Sekizawa A.
    • Int Cancer Conf J. 2017 Mar 21;6(3):104-108. doi: 10.1007/s13691-017-0287-9. eCollection 2017 Jul.
    • Pathological features and clinical behavior of Lynch syndrome-associated ovarian cancer.
    • Ryan NA, Evans DG, Green K, Crosbie EJ.
    • Gynecol Oncol. 2017 Mar;144(3):491-495. doi: 10.1016/j.ygyno.2017.01.005. Epub 2017 Jan 6.

    Letter: Ovarian carcinoma histotype in Lynch syndrome. (Gynecologic Oncology Reports)

    Letter:

    BRCA and lynch syndrome-associated ovarian cancers behave differently.

    • [Clinical Management of HBOC in Our Hospital].
    • Nomura H, Takeshima N.
    • Gan To Kagaku Ryoho. 2017 Feb;44(2):116-120.
    • [Article in Japanese]
    • Elevated Bone Turnover Markers after Risk-Reducing Salpingo-Oophorectomy in Women at Increased Risk for Breast and Ovarian Cancer.
    • Fakkert IE, van der Veer E, Abma EM, Lefrandt JD, Wolffenbuttel BH, Oosterwijk JC, Slart RH, Westrik IG, de Bock GH, Mourits MJ.
    • PLoS One. 2017 Jan 6;12(1):e0169673. doi: 10.1371/journal.pone.0169673. eCollection 2017.
    • Outcomes of Concurrent Breast and Gynecologic Risk Reduction Surgery.
    • Ma IT, Gray RJ, Wasif N, Butler KA, Cornella JL, Magrina JF, Magtibay PM, Casey WJ, Mahabir R, Rebecca AM, Hunt KS, Pockaj BA.
    • Ann Surg Oncol. 2017 Jan;24(1):77-83. doi: 10.1245/s10434-016-5479-6. Epub 2016 Aug 31.
    • The effect of referral for genetic counseling on genetic testing and surgical prevention in women at high risk for ovarian cancer: Results from a randomized controlled trial.
    • Drescher CW, Beatty JD, Resta R, Andersen MR, Watabayashi K, Thorpe J, Hawley S, Purkey H, Chubak J, Hanson N, Buist DSM, Urban N.
    • Cancer. 2016 Nov 15;122(22):3509-3518. doi: 10.1002/cncr.30190. Epub 2016 Jul 22.
    • Non-Neoplastic Conditions of the Ovaries in Grossly Normal Adnexa: A Clinicopathologic Study of 403 Completely Embedded Cases.
    • Seidman JD, Krishnan J.
    • Int J Gynecol Pathol. 2016 Nov;35(6):544-548.
    • Risk reduction and survival benefit of prophylactic surgery in BRCA mutation carriers, a systematic review.
    • Ludwig KK, Neuner J, Butler A, Geurts JL, Kong AL.
    • Am J Surg. 2016 Oct;212(4):660-669. doi: 10.1016/j.amjsurg.2016.06.010. Epub 2016 Jul 18.
    • Review
    • Surgical prevention of epithelial ovary cancer without oophorectomy: changing the future.
    • Pérez-López FR, Chedraui P.
    • Climacteric. 2016 Oct;19(5):417-8. doi: 10.1080/13697137.2016.1202914. Epub 2016 Jul 12.
    • Risk-reducing surgery on the uterine adnexa: timing and type of surgical treatment, and pathology report.
    • Signorelli M, Bogani G, Ditto A, Martinelli F, Chiappa V, Lopez C, Scaffa C, Lorusso D, Raspagliesi F.
    • Minerva Ginecol. 2016 Oct;68(5):536-43. Epub 2016 Feb 4.
    • Review
    • [Oncopathological aspects of BRCA1 and BRCA2 genes inactivation in tumors of ovary, fallopian tube and pelvic peritoneum].
    • Škapa P, Dundr P.
    • Cesk Patol. 2016 Fall;52(4):199-204.
    • [Salpingectomy in ovarian cancer prevention: Evidence behind the hypothesis and surgical implications].
    • Gómez-Pue D, Ibarrola-BuenAbad E, Lara-Núñez D, Vázquez-Alvarado AP, Pérez-Quintanilla M.
    • Ginecol Obstet Mex. 2016 Sep;84(9):614-9.
    • Review, [Article in Spanish]
    • Specifying the ovarian cancer risk threshold of 'premenopausal risk-reducing salpingo-oophorectomy' for ovarian cancer prevention: a cost-effectiveness analysis.
    • Manchanda R, Legood R, Antoniou AC, Gordeev VS, Menon U.
    • J Med Genet. 2016 Sep;53(9):591-9. doi: 10.1136/jmedgenet-2016-103800. Epub 2016 Jun 27.
    • [Current surgical practice of prophylactic and opportunistic salpingectomy in France].
    • Chene G, de Rochambeau B, Le Bail-Carval K, Beaufils E, Chabert P, Mellier G, Lamblin G.
    • Gynecol Obstet Fertil. 2016 Jul-Aug;44(7-8):377-84. doi: 10.1016/j.gyobfe.2016.05.003. Epub 2016 Jun 27.
    • [Article in French]
    • A new strategy for prophylactic surgery in BRCA women: Combined mastectomy and laparoscopic salpingo-oophorectomy with immediate reconstruction by double DIEP flap.
    • Hunsinger V, Marchac AC, Derder M, Hivelin M, Lecuru F, Bats AS, Lantieri L.
    • Ann Chir Plast Esthet. 2016 Jun;61(3):177-82. doi: 10.1016/j.anplas.2016.02.002. Epub 2016 Mar 2.
    • The lack of clinical value of peritoneal washing cytology in high risk patients undergoing risk-reducing salpingo-oophorectomy: a retrospective study and review.
    • Blok F, Roes EM, van Leenders GJ, van Beekhuizen HJ.
    • BMC Cancer. 2016 Jan 14;16(1):18. doi: 10.1186/s12885-015-2011-5.
    • 2016 Genetics Toolkit
    • Society of Gynecologic Oncology
    • Society of Gynecologic Oncology. 2016.

    News: New Toolkit Can Help Debunk Myths About Genetic Testing for Gynecologic Cancer. (Cure)

    • Prophylactic salpingectomy and prophylactic salpingoophorectomy for adnexal high-grade serous epithelial carcinoma: A reappraisal.
    • Oliver Perez MR, Magriñá J, García AT, Jiménez Lopez JS.
    • Surg Oncol. 2015 Dec;24(4):335-44. doi: 10.1016/j.suronc.2015.09.008. Epub 2015 Oct 8.
    • Review
    • Discussion: The Next Big Things in the BRCA World.
    • [No author given].
    • My Gene Counsel. 2015 Nov 4.
    • Outcomes and Cost Analysis in High-Risk Patients Undergoing Simultaneous Free Flap Breast Reconstruction and Gynecologic Procedures.
    • Del Corral GA, Wes AM, Fischer JP, Serletti JM, Wu LC.
    • Ann Plast Surg. 2015 Nov;75(5):534-8. doi: 10.1097/SAP.0000000000000156.
    • Opportunistic salpingectomy for ovarian cancer prevention.
    • Hanley GE, McAlpine JN, Kwon JS, Mitchell G.
    • Gynecol Oncol Res Pract. 2015 Sep 17;2:5. doi: 10.1186/s40661-015-0014-1. eCollection 2015.
    • Laparoscopic Salpingo-oophorectomy in Conscious Sedation.
    • Rosati M, Bramante S, Conti F, Rizzi M, Frattari A, Spina T.
    • JSLS. 2015 Jul-Sep;19(3). pii: e2015.00031. doi: 10.4293/JSLS.2015.00031.
    • Public perception of risk-reducing salpingectomy for preventing ovarian cancer.
    • Kang JH, Nam SH, Song T, Kim WY, Lee KW, Kim KH.
    • Obstet Gynecol Sci. 2015 Jul;58(4):284-8. doi: 10.5468/ogs.2015.58.4.284. Epub 2015 Jul 16.
    • Single-port versus conventional multiport access prophylactic laparoscopic bilateral salpingo-oophorectomy in high-risk patients for ovarian cancer: a comparison of surgical outcomes.
    • Angioni S, Pontis A, Sedda F, Zampetoglou T, Cela V, Mereu L, Litta P.
    • Onco Targets Ther. 2015 Jun 25;8:1575-80. doi: 10.2147/OTT.S82570. eCollection 2015.
    • Oophorectomy benefits in breast cancer patients with BRCA1 mutation.
    • Brown S.
    • Post Reprod Health. 2015 Jun;21(2):46-7.
    • Microarray analysis of differentially expressed genes in ovarian and fallopian tube epithelium from risk-reducing salpingo-oophorectomies.
    • Veskimäe K, Staff S, Tabaro F, Nykter M, Isola J, Mäenpää J.
    • Genes Chromosomes Cancer. 2015 May;54(5):276-87. doi: 10.1002/gcc.22241. Epub 2015 Feb 23.
    • Clinical management of patients at inherited risk for gynecologic cancer.
    • Powell CB.
    • Curr Opin Obstet Gynecol. 2015 Feb;27(1):14-22. doi: 10.1097/GCO.0000000000000143.
    • Review
    • Committee opinion no. 620: salpingectomy for ovarian cancer prevention.
    • [No authors listed]
    • Obstet Gynecol. 2015 Jan;125(1):279-81. doi: 10.1097/01.AOG.0000459871.88564.09.
    • Bilateral salpingo-oophorectomy and adhesiolysis with single port access laparoscopy and use of diode laser in a BRCA carrier.
    • Angioni S, Pontis A, Sorrentino F, Nappi L.
    • Eur J Gynaecol Oncol. 2015;36(4):479-81.
    • Case Report
    • Pros and Cons of Hysterectomy at the Time of Risk-reducing Removal of Ovaries and Fallopian Tubes.
    • Jessica McAlpine.
    • FORCE. Be Empowered Webinars. 2014 Dec 17.
    • Is Salpingectomy ‘The Answer’ for BRCA Carriers?
    • Ellen T- Matloff.
    • My Gene Counsel. 2014 Dec 1.
    • [The importance of screening in oncogynecology].
    • Frühauf F, Sláma J, Zikán M.
    • Ceska Gynekol. 2014 Dec;79(6):491-8.
    • Review, [Article in Czech]
    • Advances in tumor screening, imaging, and avatar technologies for high-grade serous ovarian cancer.
    • Ohman AW, Hasan N, Dinulescu DM.
    • Front Oncol. 2014 Nov 18;4:322. doi: 10.3389/fonc.2014.00322. eCollection 2014.
    • RAD51C germline mutations found in Spanish site-specific breast cancer and breast-ovarian cancer families.
    • Blanco A, Gutiérrez-Enríquez S, Santamariña M, Montalban G, Bonache S, Balmaña J, Carracedo A, Diez O, Vega A.
    • Breast Cancer Res Treat. 2014 Aug;147(1):133-43. doi: 10.1007/s10549-014-3078-4. Epub 2014 Aug 3.
    • Prophylactic mastectomy with immediate reconstruction combined with simultaneous laparoscopic salpingo-oophorectomy via a transmammary route: a novel surgical approach to female BRCA-mutation carriers.
    • Perabò M, Fink V, Günthner-Biller M, von Bodungen V, Friese K, Dian D.
    • Arch Gynecol Obstet. 2014 Jun;289(6):1325-30. doi: 10.1007/s00404-013-3133-0. Epub 2014 Jan 4.
    • First case of prophylactic salpingectomy with single port access laparoscopy and a new diode laser in a woman with BRCA mutation.
    • Angioni S, Mais V, Pontis A, Peiretti M, Nappi L.
    • Gynecol Oncol Case Rep. 2014 May 19;9:21-3. doi: 10.1016/j.gynor.2014.05.002. eCollection 2014.
    • Opportunistic salpingectomy: uptake, risks, and complications of a regional initiative for ovarian cancer prevention.
    • McAlpine JN, Hanley GE, Woo MM, Tone AA, Rozenberg N, Swenerton KD, Gilks CB, Finlayson SJ, Huntsman DG, Miller DM; Ovarian Cancer Research Program of British Columbia.
    • Am J Obstet Gynecol. 2014 May;210(5):471.e1-471.e11. doi: 10.1016/j.ajog.2014.01.003. Epub 2014 Jan 9.

    Editorial, Comment:

    Salpingectomy, why not?

    • Ki-67 and p53 expression of the fallopian tube mucosa in breast cancer patients with hereditary risk.
    • Anton A, Schott S, Kaip G, Rath M, Heil J, Aulmann S, Sinn HP.
    • Arch Gynecol Obstet. 2014 May;289(5):1079-85. doi: 10.1007/s00404-013-3062-y. Epub 2013 Nov 7.
    • Prophylactic Surgery Recommended for BRCA1 Carriers.
    • [No authors listed]
    • Cancer Discov. 2014 May;4(5):OF1. doi: 10.1158/2159-8290.CD-NB2014-042. Epub 2014 Mar 27.
    • Quantitative analysis of γ-H2AX and p53 nuclear expression levels in ovarian and fallopian tube epithelium from risk-reducing salpingo-oophorectomies in BRCA1 and BRCA2 mutation carriers.
    • Staff S, Tolonen T, Laasanen SL, Mecklin JP, Isola J, Mäenpää J.
    • Int J Gynecol Pathol. 2014 May;33(3):309-16. doi: 10.1097/PGP.0b013e31829c673b.
    • It Is Safe to Perform Gynecologic Surgery First in Patients Undergoing Combined Breast and Gynecologic Surgery.
    • Jack Basil, Rachel Sinkey, ; James C. Pavelka, J. Michael Guenther.
    • Obstetrics & Gynecology. 123(Suppl 1):182S, May 2014. doi: 10.1097/01.AOG.0000447201.43420.a0.
    • Conference abstract
    • Pure natural orifice transluminal endoscopic surgery (NOTES) involving peroral endoscopic salpingo-oophorectomy (POESY).
    • Hornemann A, Suetterlin M, Trunk MJ, Gerhardt A, Kaehler G.
    • Int J Gynaecol Obstet. 2014 Apr;125(1):86-8. doi: 10.1016/j.ijgo.2013.08.024. Epub 2014 Jan 2.
    • Case report
    • Estrogen controls the survival of BRCA1-deficient cells via a PI3K-NRF2-regulated pathway.
    • Gorrini C, Gang BP, Bassi C, Wakeham A, Baniasadi SP, Hao Z, Li WY, Cescon DW, Li YT, Molyneux S, Penrod N, Lupien M, Schmidt EE, Stambolic V, Gauthier ML, Mak TW.
    • Proc Natl Acad Sci U S A. 2014 Mar 25;111(12):4472-7. doi: 10.1073/pnas.1324136111. Epub 2014 Feb 24.

    Comment:

    Tissue-specific tumor suppression by BRCA1.

    • Prophylactic Bilateral Salpingectomy as a Prevention Strategy in Women at High-Risk of Ovarian Cancer: A Mini-Review.
    • Schenberg T, Mitchell G.
    • Front Oncol. 2014 Feb 10;4:21. eCollection 2014.
    • Revisiting the pathogenesis of ovarian cancer: the central role of the fallopian tube.
    • Dietl J.
    • Arch Gynecol Obstet. 2014 Feb;289(2):241-6. doi: 10.1007/s00404-013-3041-3. Epub 2013 Oct 8.
    • Review
    • The fallopian tube as the origin of high grade serous ovarian cancer: review of a paradigm shift.
    • Reade CJ, McVey RM, Tone AA, Finlayson SJ, McAlpine JN, Fung-Kee-Fung M, Ferguson SE.
    • J Obstet Gynaecol Can. 2014 Feb;36(2):133-40.
    • Alternatives to risk-reducing surgery for ovarian cancer.
    • Gadducci A, Sergiampietri C, Tana R.
    • Ann Oncol. 2013 Nov;24 Suppl 8:viii47-viii53. doi: 10.1093/annonc/mdt311.
    • Increased Proliferative Background in Healthy Women with BRCA1/2 Haploinsufficiency Is Associated with High Risk for Breast Cancer.
    • Nisman B, Kadouri L, Allweis T, Maly B, Hamburger T, Gronowitz S, Peretz T.
    • Cancer Epidemiol Biomarkers Prev. 2013 Nov;22(11):2110-5. doi: 10.1158/1055-9965.EPI-13-0193. Epub 2013 Aug 21.
    • Risk-reducing salpingectomy as a new and safe strategy to prevent ovarian cancer.
    • Morelli M, Venturella R, Zullo F.
    • Am J Obstet Gynecol. 2013 Oct;209(4):395-6. doi: 10.1016/j.ajog.2013.05.015. Epub 2013 May 9.

    Review:

    The role of the fallopian tube in the origin of ovarian cancer.

    Letter, Comment:

    Reply: To PMID 23583217.

    • The expression of BRCA1, P53, KAI1, and Nm23 in ovaries of BRCA1 mutation carriers after prophylactic adnexectomy.
    • Markowska J, Bar J, Mądry R, Słomska I, Mardas M, Grabowski JP.
    • Arch Gynecol Obstet. 2013 Oct;288(4):839-44. doi: 10.1007/s00404-013-2825-9. Epub 2013 Apr 4.
    • Challenging and complex decisions in the management of the BRCA mutation carrier.
    • Stan DL, Shuster LT, Wick MJ, Swanson CL, Pruthi S, Bakkum-Gamez JN.
    • J Womens Health (Larchmt). 2013 Oct;22(10):825-34. doi: 10.1089/jwh.2013.4407. Epub 2013 Aug 29.
    • Opportunistic and interventional salpingectomy in women at risk: a strategy for preventing pelvic serous cancer (PSC).
    • Kamran MW, Vaughan D, Crosby D, Wahab NA, Saadeh FA, Gleeson N.
    • Eur J Obstet Gynecol Reprod Biol. 2013 Aug;170(1):251-4. doi: 10.1016/j.ejogrb.2013.06.030. Epub 2013 Jul 21.
    • Risk-reducing salpingectomy in Canada: a survey of obstetrician-gynaecologists.
    • Reade CJ, Finlayson S, McAlpine J, Tone AA, Fung-Kee-Fung M, Ferguson SE.
    • J Obstet Gynaecol Can. 2013 Jul;35(7):627-34.
    • Mixed reviews on removing fallopian tubes to prevent ovarian cancer.
    • Kramer L.
    • CMAJ. 2013 Jun 11;185(9):E391-2. doi: 10.1503/cmaj.109-4475. Epub 2013 May 6.
    • Salpingectomy to prevent ovarian cancer: A Countercurrents Series.
    • Narod SA.
    • Curr Oncol. 2013 Jun;20(3):145-7. doi: 10.3747/co.20.1471.
    • Understanding the Needs of Women Considering Risk-Reducing Salpingo-oophorectomy.
    • Cherry C, Ropka M, Lyle J, Napolitano L, Daly MB.
    • Cancer Nurs. 2013 May-Jun;36(3):E33-8. doi: 10.1097/NCC.0b013e3182642cb5.
    • Experience of Risk-reducing Salpingo-oophorectomy for a BRCA1 Mutation Carrier and Establishment of a System Performing a Preventive Surgery for Hereditary Breast and Ovarian Cancer Syndrome in Japan: Our Challenges for the Future.
    • Hirasawa A, Masuda K, Akahane T, Tsuruta T, Banno K, Makita K, Susumu N, Jinno H, Kitagawa Y, Sugano K, Kosaki K, Aoki D.
    • Jpn J Clin Oncol. 2013 May;43(5):515-9. doi: 10.1093/jjco/hyt036. Epub 2013 Mar 13.
    • Salpingectomy: Can removing the fallopian tubes lower ovarian cancer risk?
    • Ilana Cass, Doug Levine
    • FORCE. Be Empowered Webinars. 2013 Apr 11.
    • Surgical implications of the potential new tubal pathway for ovarian carcinogenesis.
    • Chene G, Rahimi K, Mes-Masson AM, Provencher D.
    • J Minim Invasive Gynecol. 2013 Mar-Apr;20(2):153-9. doi: 10.1016/j.jmig.2012.11.010. Epub 2013 Jan 16.
    • Review
    • Psychosocial factors and uptake of risk-reducing salpingo-oophorectomy in women at high risk for ovarian cancer.
    • Meiser B, Price MA, Butow PN, Karatas J, Wilson J, Heiniger L, Baylock B, Charles M, McLachlan SA, Phillips KA.
    • Fam Cancer. 2013 Mar;12(1):101-9. doi: 10.1007/s10689-012-9585-8.
    • Gynaecological cancer: Risk reduction surgery in non-BRCA carriers–is less more?
    • [No author given]
    • Nature Reviews Clinical Oncology. doi:10.1038/nrclinonc.2012.243. 2013 Feb.
    • High-Grade Serous Tumor Arising from Fallopian Tube in a BRCA Mutation Carrier after Prophylactic Oophorectomy.
    • Lorusso D, Di Rocco R, Mancini M, Raspagliesi F.
    • Case Rep Oncol. 2013 Jan;6(1):21-4. doi: 10.1159/000346339. Epub 2013 Jan 9.
    • The role of peritoneal cytology at risk-reducing salpingo-oophorectomy (RRSO) in women at increased risk of familial ovarian/tubal cancer: Is the evidence strong enough?
    • Haldar K, Crawford R.
    • Gynecol Oncol. 2013 Jan;128(1):148-9. doi: 10.1016/j.ygyno.2012.08.019. Epub 2012 Aug 20.
    • Comment, Letter

    Editorial:

    The role of peritoneal cytology at risk-reducing salpingo-oophorectomy (RRSO) in women at increased risk of familial ovarian/tubal cancer.

    Letter, Reply:

    There is a need for routine peritoneal cytology at RRSO.

    • There is a need for routine peritoneal cytology at RRSO.
    • Manchanda R, Drapkin R, Menon U.
    • Gynecol Oncol. 2013 Jan;128(1):149-50. doi: 10.1016/j.ygyno.2012.09.031. Epub 2012 Oct 9.
    • Comment, Letter

    Letter, Comment:

    The role of peritoneal cytology at risk-reducing salpingo-oophorectomy (RRSO) in women at increased risk of familial ovarian/tubal cancer: Is the evidence strong enough?

    Editorial:

    The role of peritoneal cytology at risk-reducing salpingo-oophorectomy (RRSO) in women at increased risk of familial ovarian/tubal cancer.

    • Prophylactic Salpingectomy and Delayed Oophorectomy as an Alternative for BRCA Mutation Carriers.
    • Kwon JS, Tinker A, Pansegrau G, McAlpine J, Housty M, McCullum M, Gilks CB.
    • Obstet Gynecol. 2013 Jan;121(1):14-24. doi: http://10.1097/AOG.0b013e3182783c2f.

    Editorial/Comment:

    Ideal Risk Reduction Management for Women With BRCA Gene Mutations: Still Not There Yet.

    • [Methods of surgical prevention of breast cancer and of ovarian cancer in BRCA mutation carriers].
    • Bit-Sava EM, Belogurova MB, Imianitov EN, Balandov SG, Korniushin OV, Borisov MK.
    • Vopr Onkol. 2013;59(2):5-11.
    • Review, [Article in Russian]
    • Risk-reducing salpingo-oophorectomy and prophylactic mastectomy among BRCA mutation "previvors".
    • Holman L, Brandt A, Daniels M, Arun B, Keeler E, Gershenson D, Sun C, Lu K.
    • Gynecol Oncol. 2012 Oct;127(1 Suppl):S17. doi: 10.1016/j.ygyno.2012.07.048.
    • New findings presented on metastatic breast cancer and bilateral oophorectomy.
    • Printz C.
    • Cancer. 2012 Jun 1;118(11):2778. doi: 10.1002/cncr.27643.
    • Bilateral oophorectomy, body mass index, and mortality in U.S. women aged 40 years and older.
    • McCarthy AM, Menke A, Ouyang P, Visvanathan K.
    • Cancer Prev Res (Phila). 2012 Jun;5(6):847-54. doi: 10.1158/1940-6207.CAPR-11-0430. Epub 2012 May 3.
    • The potential for risk stratification in the management of ovarian cancer risk.
    • Pharoah PD.
    • Int J Gynecol Cancer. 2012 May;22 Suppl 1:S16-7. doi: 10.1097/IGC.0b013e318251caaf.
    • Review
    • Screening for gynaecologic cancers in genetically predisposed women.
    • Dreyer G.
    • Best Pract Res Clin Obstet Gynaecol. 2012 Apr;26(2):267-82. doi: 10.1016/j.bpobgyn.2011.11.002. Epub 2012 Feb 22.
    • Review
    • Non-cancer endpoints in BRCA1/2 carriers after risk-reducing salpingo-oophorectomy.
    • Cohen JV, Chiel L, Boghossian L, Jones M, Stopfer JE, Powers J, Rebbeck TR, Nathanson KL, Domchek SM.
    • Fam Cancer. 2012 Mar;11(1):69-75. doi: 10.1007/s10689-011-9480-8.
    • Physician data query (PDQ®) update.
    • [No authors listed]
    • J Natl Cancer Inst. 2012 Feb 8;104(3):176. doi: 10.1093/jnci/djs025. Epub 2012 Jan 23.
    • The role of peritoneal cytology at risk-reducing salpingo-oophorectomy (RRSO) in women at increased risk of familial ovarian/tubal cancer.
    • Manchanda R, Drapkin R, Jacobs I, Menon U.
    • Gynecol Oncol. 2012 Feb;124(2):185-91. doi: 10.1016/j.ygyno.2011.10.017. Epub 2011 Oct 20.
    • Commentary

    Comment, Letter:

    The role of peritoneal cytology at risk-reducing salpingo-oophorectomy (RRSO) in women at increased risk of familial ovarian/tubal cancer: Is the evidence strong enough?

    Comment, Letter:

    There is a need for routine peritoneal cytology at RRSO.